MetaVia's Obesity Drug DA-1726 Completes Dose Titration in Phase 1, Topline Data on Track for Q4 2026
MTVA sits 64% above its 52-week low of $0.966.
Summary
MetaVia's Phase 1 trial for obesity drug DA-1726 hit a key milestone with all patients reaching target doses, and topline data remains on track for Q4 2026.
Key Events · Product Development and Regulatory · MTVA
-
Dose Titration Completed
All active patients in Part 3 of the Phase 1 trial for DA-1726 have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg in both cohorts.
-
Topline Data Timeline Confirmed
The company reiterated that topline data from the Phase 1 trial is on track for release in the fourth quarter of 2026.
-
Tolerability Profile Reinforced
Reaching the highest planned dose levels in all active patients supports the favorable tolerability of DA-1726, a potential competitive advantage over existing obesity therapies.
-
Prior Efficacy Data Highlighted
Previously reported Phase 1 MAD data showed 9.1% mean weight loss at the 48 mg dose in just 8 weeks, along with improvements in waist circumference and glycemic measures.
Analysis · MTVA · Life Sciences
MetaVia announced that all active patients in Part 3 of its Phase 1 trial for obesity drug DA-1726 have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. This milestone de-risks the trial's tolerability profile and keeps the program on schedule for topline data in Q4 2026. The update reinforces the drug's competitive positioning in the obesity market, where prior data showed 9.1% weight loss in 8 weeks. For a micro-cap biotech with a going concern warning and recent dilutive financing, positive clinical progress is critical to maintaining investor confidence and partnership potential.
At the time of this filing, MTVA was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.97 to $19.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.